Edition:
United Kingdom

Galapagos NV (GLPG.AS)

GLPG.AS on Amsterdam Stock Exchange

85.52EUR
22 Jun 2018
Change (% chg)

€0.80 (+0.94%)
Prev Close
€84.72
Open
€84.72
Day's High
€85.88
Day's Low
€84.68
Volume
217,908
Avg. Vol
397,756
52-wk High
€98.82
52-wk Low
€61.88

Latest Key Developments (Source: Significant Developments)

Galapagos Increases Share Capital Through Warrant Exercises
Wednesday, 20 Jun 2018 

June 20(Reuters) - GALAPAGOS NV ::ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES.ISSUED 102,801 NEW ORDINARY SHARES, FOR A TOTAL CAPITAL INCREASE OF EUR 1.3 MLN.EXECUTIVE COMMITTEE MEMBERS COMMITTED TO EXERCISE MINIMUM NUMBER OF WARRANTS.CEO ONNO VAN DE STOLPE EXERCISED 15,000 WARRANTS.THREE OTHER EXECUTIVE COMMITTEE MEMBERS EXERCISED AGGREGATE NUMBER OF 45,000 WARRANTS.  Full Article

Gilead, Galapagos Announce Results With Filgotinib In Phase 2 EQUATOR Study In Psoriatic Arthritis
Wednesday, 30 May 2018 

May 30 (Reuters) - Galapagos NV : :GILEAD AND GALAPAGOS ANNOUNCE RESULTS WITH FILGOTINIB IN THE PHASE 2 EQUATOR STUDY IN PSORIATIC ARTHRITIS AND PROGRESSION INTO PHASE 3 FOR THE SELECTION STUDY IN ULCERATIVE COLITIS.GALAPAGOS NV - EQUATOR ACHIEVES PRIMARY ENDPOINT OF ACR20 RESPONSE AT WEEK 16.GALAPAGOS - CO TO GET $15 MILLION PAYMENT FROM GILEAD FOR PROGRESSION INTO PHASE 3 OF PHASE 2B/3 SELECTION STUDY OF FILGOTINIB IN ULCERATIVE COLITIS.GALAPAGOS NV - FILGOTINIB WAS GENERALLY WELL-TOLERATED IN EQUATOR TRIAL, WITH NO NEW SAFETY SIGNALS OBSERVED.GALAPAGOS NV - THERE WAS ONE SERIOUS INFECTION IN FILGOTINIB GROUP, A PATIENT WHO EXPERIENCED PNEUMONIA WITH A FATAL OUTCOME IN TRIAL.GALAPAGOS NV - IN TRIAL ONE OTHER PATIENT RECEIVING FILGOTINIB DEVELOPED HERPES ZOSTER.GALAPAGOS NV - THERE WERE NO CASES OF OPPORTUNISTIC INFECTION, TUBERCULOSIS, THROMBOEMBOLISM, OR MALIGNANCY IN TRIAL.  Full Article

ProQR And Galapagos Announce Research Collaboration
Monday, 8 Jan 2018 

Jan 8 (Reuters) - Galapagos Nv ::PROQR AND GALAPAGOS ANNOUNCE RESEARCH COLLABORATION ON FIBROSIS TARGETS USING PROQR’S AXIOMER® TECHNOLOGY.PROQR THERAPEUTICS - UNDER AGREEMENT, TWO COMPANIES WILL WORK TOGETHER TO DISCOVER NOVEL AXIOMER EONS AGAINST FIBROSIS TARGETS SELECTED BY GALAPAGOS.PROQR THERAPEUTICS NV- TARGETS THAT WILL BE PURSUED IN COLLABORATION AND FINANCIAL DETAILS ABOUT COLLABORATION ARE NOT DISCLOSED.  Full Article

Galapagos NV reports Q3 loss of ‍1.75​ euro per share
Thursday, 26 Oct 2017 

Oct 26 (Reuters) - Galapagos NV -:Galapagos NV qtrly ‍revenues 106.4 million euro versus 65 million euro​.Galapagos NV qtrly loss per share ‍1.75​ euro.Galapagos NV says ‍we anticipate cash burn for full year to be at lower end of guidance of euro 135 million - 155 million​.  Full Article

Galapagos gets orphan drug designation in EU for GLPG1690 in idiopathic pulmonary fibrosis
Tuesday, 6 Sep 2016 

Galapagos NV :Orphan drug designation in European Union for GLPG1690 in idiopathic pulmonary fibrosis.  Full Article

BRIEF-Galapagos Increases Share Capital Through Warrant Exercises

* ANNOUNCED ON WEDNESDAY SHARE CAPITAL INCREASE ARISING FROM WARRANT EXERCISES